Pharmacologic Management of Stage 2 Hypertension
Start combination therapy with two antihypertensive agents from different classes, specifically a RAS blocker (ACE inhibitor or ARB) combined with either a calcium channel blocker or thiazide diuretic—making option (b) benazepril and amlodipine the best answer.
Rationale for Combination Therapy in Stage 2 Hypertension
This patient presents with stage 2 hypertension (BP ≥160/100 mm Hg on initial visit, confirmed at ≥140/90 mm Hg on repeat), which mandates prompt pharmacologic intervention alongside lifestyle modifications. 1
Why Combination Therapy is Superior
The 2024 ESC guidelines explicitly recommend combination BP-lowering treatment as initial therapy for most patients with confirmed hypertension (BP ≥140/90 mm Hg), with preferred combinations being a RAS blocker (ACE inhibitor or ARB) with either a dihydropyridine calcium channel blocker or diuretic. 1
Patients with stage 2 hypertension and BP ≥160/100 mm Hg should be promptly treated with consideration for initiating two antihypertensive agents of different classes. 1
Combination therapy achieves more effective BP control compared to monotherapy, with evidence showing that increasing from single-class to dual-class therapy is associated with a 42% increased odds of achieving BP control (OR 1.42; 95% CI 1.22-1.64). 2
Single-pill combinations are preferred when using combination therapy to improve adherence. 1
Why Not Monotherapy Options
Option (c) hydrochlorothiazide alone represents monotherapy, which is less effective for stage 2 hypertension where BP is ≥20/10 mm Hg above target. 3
Option (d) amlodipine alone is similarly inadequate as monotherapy for this degree of BP elevation. 3
Why Not Beta-Blocker Combinations
Option (a) atenolol and chlorthalidone includes a beta-blocker, which is not recommended as first-line therapy unless there are compelling indications such as angina, post-myocardial infarction, heart failure with reduced ejection fraction, or need for heart rate control—none of which are present in this healthy 49-year-old man. 1
Beta-blockers should be combined with other major BP-lowering drug classes only when compelling indications exist. 1
Treatment Target and Monitoring
The target systolic BP should be 120-129 mm Hg in most adults, provided treatment is well tolerated. 1
For adults under 65 years, the target is <130/80 mm Hg. 3
Reassess electrolytes and renal function 2-4 weeks after initiating RAS inhibitor or diuretic therapy. 1
Monitor for orthostatic hypotension, document adherence, and adjust doses upward as necessary to achieve BP control. 1
Common Pitfalls to Avoid
Do not delay combination therapy in stage 2 hypertension—monotherapy will likely be insufficient when BP is ≥20/10 mm Hg above target. 1, 2
Avoid combining two RAS blockers (ACE inhibitor plus ARB)—this is explicitly not recommended. 1
Do not use beta-blockers as first-line therapy in the absence of compelling indications, as they are less effective at reducing cardiovascular events compared to the four major first-line classes. 1, 3